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Abstract 
Brugia malayi is one of three species of nematode known to cause lymphatic filariasis 
(LF) in humans. LF infects over 120 million people, causing debilitating disease. Various global 
programs have been launched in the past 20 years to eliminate LF. These programs have greatly 
scaled up the resources and efforts allocated to halting the transmission and reducing disease 
burden. Only a few drugs are used to treat LF, and resistance is thus a devastating possibility. 
Research aimed at identifying new drug targets could therefore prove essential in elimination of 
LF.  
Genetic manipulation of B. malayi has been limited to transient transfections. A 
transfection system allowing for stable integration of transgenic sequences into the nuclear 
genome of this parasite would enable more robust studies that could lead to identification of 
novel drug targets and vaccine candidates. The piggyBac (pB) transposon system has been 
successfully applied to develop a stable transfection system in a variety of species. This system 
involves two plasmids, a helper and a donor. The donor plasmid contains the target DNA and a 
selectable marker flanked by specific inverted terminal repeat (ITR) regions. The helper plasmid 
expresses the pB transposase that will catalyze the precise integration of any DNA report tools 
necessary to adapt the pB system in B. malayi. Three versions of the donor plasmid were 
constructed, each containing a Gaussia Luciferase (GLuc) selectable marker but differing only 
by the fluorescent protein expressed. The construct containing a YFP gene was used to transfect 
embryos via biolistics to test whether YFP and GLuc are expressed 
1	
			
Chapter One: Introduction 
Lymphatic filariasis – the disease and its control 
Filarial parasitic nematodes threaten hundreds of millions of people worldwide, mostly in 
developing areas. Lymphatic filariasis (LF), caused by Wuchereria bancrofti and two Brugia 
species, is a neglected tropical disease that commonly leads to elephantiasis, hydrocele, and 
lymphedema (WHO, 2017).  
 Filarial parasites have a complex life cycle, involving stages in both a mosquito vector 
and mammalian host. The infectious third-stage filarial larvae (L3) are injected into a person by 
an infected mosquito during a blood meal. These larvae develop into adults that reside in the 
lymphatics, most commonly in the extremities and male genitalia. The adults will produce an 
average of 10 thousand microfilariae a day that migrate from the lymph to the blood channels 
where they can be ingested by a mosquito, facilitated by a periodicity that causes peak 
concentrations to coincide with the local feeding habits of the mosquito vector. Once inside a 
mosquito, the microfilariae molt twice to become L3 larvae and can infect another person (CDC 
DPDx, 2016; Taylor et al., 2010).  
In the year 2000, over 120 million people worldwide were infected with lymphatic 
filariasis (LF) and approximately 1 billion people in 54 countries were at risk (WHO, 2017). This 
led to the launch of the Global Programme to Eliminate Lymphatic Filariasis (GPELF) by the 
WHO in 2000. The GPELF, visualized in Figure 1, utilizes a multimodal approach consisting of 
mass drug administration (MDA), vector control and integrated vector management (VC/IVM), 
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and Morbidity management and disability prevention in populations with LF (MMDP) (Ichimori 
et al., 2014).  
 
Figure 1: Global strategy to eliminate lymphatic filariasis (Ichimori et al., 2014) 
Open access source: http://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0003328 
 
Since the launch of GPELF, the London declaration was signed in 2012 and committed to 
eliminating LF by 2020, the Bill & Melinda Gates Foundation called for eradication by 2030, 
and the UN General assembly specifically targeted all neglected tropical diseases (NTDs) for 
elimination by 2030 (Rebollo & Bockarie, 2016). All of these initiatives have dramatically 
scaled up the resources and efforts to reduce the incidence and burden of LF. 
Between 2000 and 2012, the MDA program resulted in 4.45 billion treatments being 
consumed by people living in endemic areas, leading to an estimated 96.7 million (Ramaiah & 
Ottesen, 2014). Seven billion treatments have been consumed as of today. The economic benefit 
of GPELF, in terms of amount saved over the lifetimes of the benefit cohorts, has been estimated 
to be between US$69.30–150.7 billion (Turner et al., 2016). 
There are four main classes of drugs used to treat filarial diseases: diethylcarbamazine 
(DEC), benzimidazoles (notably, albendazole), avermectins, and oxytetracyclines (which affect 
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the Wolbachia endosymbiont); the first three affect the primarily the microfilariae in the blood 
(Scott & Ghedin, 2009). The current recommendation by the WHO is annual DEC and 
albendazole, though research has shown that including ivermectin (a derivative of avermectin) 
may improve microfilariae clearance (Ismail et al., 2001). The WHO also recommends 
preventive chemotherapy and transmission control (PCT) as the first-line strategy to achieve 
transmission interruption.  
 MDA will lead to stronger selective pressure on these parasites, potentially leading to the 
emergence of drug-resistant strains. New treatments could provide essential to eliminating LF, 
should substantial resistance arise.  
 
Genetic manipulation of Brugia malayi 
The filarial genome project was launched in 1994, with the goal of developing a 
framework to study the genome of human filarial parasites. Brugia malayi was selected as the 
organism of choice for this project, as it was the only filarial parasite readily maintained in small 
laboratory animals (Unnasch, 1994).  
In following few years, over 22,000 expressed sequence tags (ESTs), short fragments of 
cDNA used to identify genes, had been produced from B. malayi and deposited in the public 
databases by laboratories from all over the world (Blaxter et al., 2002). While these studies were 
useful for gene discovery, new methods were needed to study gene function and regulation for B. 
malayi.  
Reverse genetic approaches have been successfully used to study the free-living 
nematode Caenorhabditis elegans. Transient transfection by microinjection and particle 
bombardment (biolistics) were successfully used to introduce exogenous DNA into C. elegans, 
and later in B. malayi (Higazi et al., 2002). In a biolistic transfection, concentrated DNA is 
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precipitated onto small gold particles and propelled into embryos under high pressure; this 
method has been employed to study gene regulation in B. malayi (Shu et al., 2003; Higazi and 
Unnasch, 2004; Higazi et al., 2005; de Oliveira et al., 2008; Liu et al., 2010). Transient 
transfections are particularly limiting for studying parasites with complex life cycles, as the 
exogenous DNA introduced is not inherited. In a biolistic transfection, the transfected embryos 
are rendered developmentally incompetent. The genome of B. malayi was sequenced and 
compared to that of C. elegans, providing a foundation for future genetic studies (Ghedin et al., 
2007).  
Xu et al. (2011) demonstrated a novel method of transfecting developmentally competent 
B. malayi larvae, using a method of chemical transfection in cell culture while inducing the 
molting of L3 larvae to increase parasite permibility. Reporter activity was detected from adults 
and microfilariae retrieved from jirds (mammalian host used to maintain B. malayi). While this 
study demonstrated a method of transfecting the parasites without rendering them 
developmentally incompetent, the transgenic sequences introduced were probably not inherited 
in a Mendelian fashion. A stable method of transfection allowing the integration of transgenic 
DNA into the nuclear genome of B. malayi would enable more robust genetic studies 
 The piggyBac (pB) transposon system has been applied to a wide variety of invertebrates 
and vertebrates (Lok, 2013). Of particular relevance, the pB system was utilized to integrate 
transgenes into the genome of the parasitic nematode Strongyloides ratti (Shao et al., 2012). 
Large inserts (up to 14 kb) have been delivered without a significant loss in efficiency (Vargas et 
al., 2016) 
 The pB transposon system utilizes two plasmids to enable stable insertional mutagenesis: 
a donor and a helper. The donor plasmid contains the DNA targeted for integration, flanked by 
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the inverted terminal repeats (ITR) region. The helper plasmid expresses the pB transposase, 
which catalyzes that integration of DNA flanked by ITRs into the TTAA sites of the 
chromosomes (Balu & Adams, 2006). Adapting the methods from Xu et al. (2011) to introduce 
the proper donor and helper plasmids could lead to the development of a stable transfection 
system using the pB system. 
Objective 
The goal of this project was to design a donor plasmid that could be used in a piggyBac 
transfection system. A plasmid designed for piggyBac transfection with a secreted Gaussia 
luciferase (GLuc) selectable marker flanked by ITRs, with its expression driven by the HSP70 
promoter and its 3’UTR was the starting point for this process. While GLuc is a sensitive 
reporter assay that can confirm a successful transfection, it does not allow for positive selection 
of transfected parasites or a direct inspection to observe localization. For this reason, we planned 
to use a fluorescent protein as a reporter assay. Due to reported autofluorescence, three different 
fluorescent proteins were chosen: GFP, YFP, and CherryRed (Table 1); all were purchased from 
addgene (Cambridge, MA). 
Table 1. Fluorescent proteins chosen. 
Name Ex Em Backbone plasmid  Expression spp. 
GFP 488 507 pCS2+8NeGFP C. elegans 
YFP 516 529 pCS2+8NmCitrine C. elegans 
CherryRed 587 610 pCS2+8NmCherry C. elegans 
 
 The BmRPS12 promoter, which drives the expression of the 12 kDa small subunit 
ribosomal protein gene (de Oliveira et al., 2008), was picked to drive the expression of the 
fluorescent proteins. This promoter, like the HSP70 promoter, has been mapped in detail. The 
donor plasmid was then transfected into embryos by biolistic transfection to test the expression 
efficacy.  
6	
 
 
 
 
Chapter Two: Materials & Methods 
 
General Methods 
Polymerase chain reaction (PCR) 
PCR was used to produce large quantities of the desired inserts and to confirm that an 
insert was present. 
 
Restriction enzyme (RE) digest 
Restriction enzymes (REs) are endonucleases that recognize specific nucleotide 
sequences and cleave the DNA in a predictable manner. In order to engineer an insert into a 
vector, restriction enzymes are used to linearize the insert and vector, and produce 
complementary nucleotide overhangs. These complementary overhangs will allow the insert and 
vector to be annealed together via hydrogen bonding. As will be discussed later, DNA ligase can 
then join the adjacent strands in a ligation reaction. 
 
DNA extraction 
Following RE digest, DNA was extracted from solutions using either a phenol-
chloroform extraction or an agarose gel extaction. For a phenol-chloroform extraction, an equal 
volume of phenol:chloroform is added to a DNA sample. The phenol:chloroform denatures the 
proteins (i.e. RE enzymes), which are then separated from DNA by centrifugation. The DNA is 
then purified by an ethanol precipitation, which involves precipitating DNA out of a solution by 
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concentrated salt and cold temperature. Once precipitated, the DNA can be pelleted by 
centrifugation and further washed by 70% ethanol. The DNA is then dissolved in 1X TE. 
An agarose gel extraction is used to separate and purify two strands of DNA. This 
method is used when an insert is amplified from plasmid DNA and to remove an insert from an 
undesired vector. The sample is run on an agarose gel, which separates linear strands of DNA by 
size, and extracted using the Wizard® SV Gel and PCR Clean-Up System kit (Promega). 
 
Heat-shock transformation 
A heat-shock reaction allows the introduction a plasmid into engineered E. coli cells to 
produce large, stable quantities of the plasmid or confirm that a ligation reaction was successful. 
The protocol varies according to cells used.  
 
PCR screen 
Following a transformation, up to 40 colonies can be screened for presence of a plasmid 
containing the desired insert. Colonies are picked an grown overnight in LB containing 100 
ng/µL of ampicillin. Following incubation, 100µL of solution is transferred to 1.7 mL eppendorf 
tube and boiled at 100ºC for 10 minutes on a heating block, and subsequently centrifuged for 5 
minutes; this method allows for quick production of a DNA-containing solution that can be used 
as a template in a PCR.  
Two different types of PCR screens can be run: directional or non-directional, differing 
only by primers used in reaction. A non-directional PCR screen uses a forward and reverse 
primer flanking the multiple cloning site, while a directional PCR will use a flanking primer and 
an insert-specific primer, each of opposite directions.  
PCR samples are run on an agarose gel to confirm the presence of an insert. 
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High quality plasmid miniprep 
The plasmid from a liquid bacterial suspension of less than 5 ml is isolated and purified 
using the QIAprep Spin Miniprep Kit (Qiagen). 
 
Sequencing 
The plasmid from a liquid bacterial suspension of less than 5 ml is isolated and purified 
using the QIAprep Spin Miniprep Kit (Qiagen). The purified plasmids are then sent to Eurofins 
Genomics for sequencing, according to their instructions. Analysis of the sequencing results is 
conducted via BLAST search (NIH NCBI BLASTn). 
 
Preparation of bacterial glycerol stock 
 Bacterial cultures containing a desired plasmid will be stored with 25% glycerol at -80ºC 
for long-term storage. This stock is prepared by mixing 500µL of 50% glycerol with 500µL of 
bacterial solution in a cryopreservation vial. 
 
Inserting Multiple Cloning Site (MCS) 
Designing and preparing MCS insert for cloning 
The sequence of the parental donor plasmid was analyzed to find all non cutters, or 
restriction enzymes whose recognition site was absent in the plasmid. Eight non-cutters were 
chosen, one of which (BclI) was chosen for the MCS to be cloned into. The rest were arranged to 
allow maximal overlap, shortening the total length (Table 2).  
 
 
Table 2. Full MCS designed.  Overlapping regions are underlined.  
BclI NdeI AatII SmaI ClaI MluI BglII BclI 
TGATCA CATATG GACGTC CCCGGG ATCGAT ACGCGT AGATCT TGATCA 
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Two oligonucleotides, containing the full MCS, were designed to form 4 base-pair 5’ 
overhangs when annealed (Fig. 2). Approximately 5 µM of these individual oligonucleotides 
were phosphorylated with 10 units of T4 polynucleotide kinase (NEB) in a solution containing 1 
mM of ATP and incubated at 37ºC for 30 minutes. After inactivating the kinase, the 
phosphorylated oligonucleotides were annealed in a thermocycler by heating to 100ºC for 3 
minutes and subsequently cooling to 25ºC at a rate of -1ºC every 30s. 
1. Primers designed and ordered 
Fwd: 5’ GATCATATGACGTCCCGGGATCGATACGCGTAGATCT 3’ 
Rev: 5’ GATCAGATCTACGCGTATCGATCCCGGGACGTCATAT 3’ 
2. Oligonucleotides individually phosphorylated 
3. Annealed to leave 4bp overhangs: 
5’ GATCATATGACGTCCCGGGATCGATACGCGTAGATCT 3’ 
3’     TATACTGCAGGGCCCTAGCTATGCGCATCTAGACTAG 5’ 
Figure 2. Generating MCS insert 
 
Preparing the vector for insertion of MCS 
Site-directed mutagenesis was used to introduce a BclI site downstream of the HSP70 3’ 
UTR and upstream of the ITR2 site. Two overlapping 40bp primers with a central mutation site 
were designed to introduce a 2bp change in the sequence (Fig. 3). The reagents and protocol 
were provided by the GENEART® Site-Directed Mutagenesis System kit (ThermoFisher, USA).  
 
Original: 5’ ACGCGGTCGTTATAGTTCAAAATCAGTGACACTTACCGCA 3’ 
Mutg_Fwd: 5’ ACGCGGTCGTTATAGTTCATGATCAGTGACACTTACCGCA 3’ 
Mutg_Rev: 5’ TGCGGTAAGTGTCACTGATCATGAACTATAACGACCGCGT 3’ 
Figure 3. Mutagenesis primers.   
Red represents the mutated base-pairs 
 
 
 The linearized vector was then transformed into DH5ɑ-T1 cells provided by the 
manufacturer. Six colonies were picked, grown overnight in LB media containing 100 ng/µL of 
ampicillin, purified, and sent for sequencing to confirm presence of desired mutation and 
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absence of undesired mutations. Once confirmed, 5µg of the vector was digested with BclI and 
dephosphorylated with 5 units of calf intestinal alkaline phosphatase. The vector was then 
extracted via phenol/chloroform extraction and purified by ethanol precipitation. 
 
MCS ligation 
The MCS insert was ligated into the vector at a 3:1 molar ratio by incubating at 16ºC for 
16 hours. The mixture, listed in (Table 3), was assembled in an RNase-free, thin-walled tube 
along with 1X ligation buffer. Two control reactions were run: one with no insert, to determine 
how much self-ligation is present, and one with no insert and no T4 ligase, to determine how 
much uncut vector is in the plasmid. 
 
Table 3. MCS ligation components 
 
Ligation (µL) Control 1 (µL) Control 2 (µL) 
H2O 26.3 29.3 27.3 
10X Ligase buffer 3.5 3.5 3.5 
Vector 2.2 2.2 2.2 
Insert 1.0 0.0 0.0 
T4 Ligase 2.0 0.0 2.0 
TOTAL 35.0 35.0 35.0 
 
 
 
 
 
Confirmation of Ligation 
A PCR screen was run on selected colonies against a control to analyze relative size 
difference. Positive hits were sent for sequencing, one colony was stored in 25% glycerol at  
-80ºC. 
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Cloning methods for fluorescent protein constructs 
 
 
Figure 4. General overview of construct designs.  
Six different ligations were conducted to generate 5 different constructs 
 
Primer design and PCR amplification 
The primers used in this study are provided in Table 4.  The primers for the RPS12 
promoter were designed with synthetic Nde1 sites, while its 3’ UTR was amplified with a 
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synthetic BglII site to be cloned into the corresponding site. All the primers for the fluorescent 
proteins were designed for the fluorescent protein genes to be cloned into the MluI site of the 
MCS. The sequences of CherryRed and YFP had identical 5’ and 3’ 30 bp sequences, allowing 
them to be amplified using the same primers. All fluorescent proteins were amplified from the 
fluorescent protein backbones purchased from Addgene (Cambridge, MA).  
Insert DNA was amplified via PCR according to the components and program in Table 5 
and Table 6. 
 
Table 4. Primers used for sequencing and amplification of inserts 
Name Sequence 
pB-Screen_Fwd 
pB-Screen_Rev 
5’ CGTATGAGTTAAATCTTAAAAGTCACG 3’ 
5’ GTGCATTTAGGACATCTCAGTC 3’ 
RPS12-Pro_Fwd 
RPS12-Pro_Rev 
5’ GGGCATATGGCTTAAGGAGAATTTTTAAAAAACTATAGAG 3’  
5’ GGGCATATGCATGTTCAGCAGTTGTCCTCGAT 3’ 
RPS12-3UTR_Fwd 
RPS12-3UTR_Rev 
5’ GGGAGATCTTGACTATTGTTTGTTTATTGTTTGTATTGAAG 3’  
5’ GGGAGATCTGCCCAAGCAATTTCGAATGA 3’ 
Cherry/YFP_Fwd 
Cherry/YFP_Rev 
5’ GGGACGCGTGTGCATTTAGGACATCTCAGTC 3’ 
5’ GGGACGCGTCTTGTACAGCTCGTCCATGC 3’ 
GFP_Fwd   
GFP_Rev 
5’ GGGACGCGTCGGAGCAAGCTTGATTTAGG 3’ 
5’ GGGACGCGTTGGTTTGTCCAAACTCATCAA 3’ 
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Table 5. PCR components for insert amplification 
Components (Starting Concentration) Volume (µL) 
DNase-free water 27.5 
10X PCR buffer 5.0 
MgCl2 (50mM) 4.0 
dNTPs (2 mM) 10.0 
Forward Primer (50 µM) 0.5 
Reverse Primer (50 µM) 0.5 
Taq DNA polymerase (5 U/µL) 0.5 
DNA template 2.0 
TOTAL 50 
 
 
Table 6. PCR thermocycler program for insert amplification 
 Temperature (ºC) Duration # of Cycles 
Denaturation 94ºC 3 min 1 
Amplification 
94ºC 
(Tm-5)ºC 
68ºC 
30 sec 
40 sec 
1.5 min 
30 
Final extension 68ºC 20 min 1 
 
4ºC Until storage 1 
 
 
Strata ligation 
All of the inserts were amplified to be cloned into the linear StrataClone PCR cloning 
vector. This vector contains topoisomerase-charged ends with modified uridine overhangs (that 
binds to 3’ adenosine overhangs of PCR products) and a loxP recognition sequence that enables 
recombination to create a circular DNA molecule containing the PCR product 
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The PCR product and vector were incubated for 5 minutes at room temperature and 
subsequently transformed into Cre recombinase-expressing cells provided by manufacturer. Cre 
recombinase catalyzes the recombination between the two loxP sites, resulting in a circular 
plasmid containing the PCR product. The vector contains a lacZ´ α-complementation cassette, 
which enables blue-white screening.  Up to 40 white colonies are grown in liquid media and 
screened by PCR for presence of insert.   
 
Preparation of insert and vector 
Two separate colonies containing the proper vector and the proper insert in a strata vector 
were purified using the QIAGEN Plasmid Midiprep kit.  Once purified, 10µg of insert and 5µg 
of vector were separately digested by the same restriction enzyme (to produce complementary 
overhangs). The insert was extracted via agarose gel extraction to separate it from the Strata 
vector and the vector was purified via phenol/chloroform extraction, followed by an ethanol 
precipitation. 
 
Ligation of insert into vector 
Two different protocols were used for ligations. The first protocol was used to ligate the 
RPS12 promoter & its 3’ UTR, as well as YFP into the final vector. The second protocol was 
used to ligate CherryRed and GFP into the vector. In the first protocol, the insert to vector molar 
ratio was 3 to 1. The components added were according to Table 7. The solutions were incubated 
at 16ºC for 16 hours and the T4 ligase was inactivated at 65ºC for 10 minutes (Table 7). 
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Table 7. Ligation 1 components 
 
Ligation (µL) Control 1 (µL) 
H2O To 35µL To 35µL 
10X Ligase buffer 3.5 3.5 
Insert:Vector 3:1 No insert 
T4 Ligase 1.0 1.0 
TOTAL 35.0 35.0 
  
This protocol did not yield any success for the ligations of CherryRed and GFP; it was 
therefore modified in the hopes of increasing ligation efficiency. The insert:vector ratio was 
increased to 6:1 and the total volume was reduced to 20 µL. The insert and vector were heated at 
65ºC for 5 minutes prior to adding ligase buffer and ligase to disrupt an insert-to-insert or vector-
to-vector sticky end interactions. The 16ºC incubation was shortened to 15 hrs and preceded by 
30 minutes at 4ºC, while followed by 30 minutes at 22ºC (Table 8). 
 
Table 8. Ligation 2 thermocycler program 
Temperature (ºC) Duration 
4ºC 30 min 
16ºC 15 hrs 
22ºC 30 min 
65ºC 10 
4ºC Infinite 
 
 Following ligation, 3µL of the ligation solution was transformed into Subcloning 
Efficiency™ DH5α™ Competent Cells (ThermoFisher) according to the manufacturer’s 
protocol. Up to 40 colonies were picked and screened by PCR for the presence of insert in the 
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proper orientation. Up to 3 positive hits were sent for sequencing and one confirmed colony was 
stored in glycerol at -80ºC. 
 
Biolistic transfection 
Approximately 30 mg of gold beads (0.6µm diameter) were washed with 1ml of 70% 
ethanol once folowed by three washes with 1ml nuclease free water. The beads were then 
resuspended in 500µL of 50% glycerol, giving a concentration of 60 mg/ml, and stored at 4ºC. 
The beads were resuspended in the solution by placing on a platform vortex for 15 minutes; 50 
µL of this solution are transferred to another centrifuge tube for use in a single transfection.  
The new tube was placed on the platform vortex while the remaining components were 
added in order: 10µL of 2µg/µL purified DNA in water, 55µL of 2.5 M CaCl2, and 22µL of 0.1 
M of spermidine. After the sample was vortexed for 3 more minutes and allowed to settle, the 
beads were washed once with 280µL of 75% ethanol and once with 280µL of absolute ethanol. 
The beads were then resuspended in 18µL of absolute ethanol, with 6µL loaded onto 
macrocarriers. 
The embryos are isolated by dissection of adult female worms. Five female worms were 
used per transfection. The adult worms are visible with the naked eye and can be easily isolated 
on a 3.5 cm petri dish in a flow hood. The worms were vigorously diced using a curved bladed 
scalpel to release the embryos. Embryos were collected into a 1.7 mL tube in around 500µL of 
CF-RPMI. The embryos were then centrifuged at 6000 x g and resuspended in 30µL of CF-
RPMI. These embryos are then spread in the center of a 3.5 cm petri dish 
The DNA/bead-coated macrocarrier, the embryo-containing dish, and an 1100 PSI break 
disk were all properly loaded onto a biolistic unit (BioRad, Hercules, CA). The embryos were 
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then bombarded with the beads at 1100 PSI under a vacuum of 12.5 in of mercury. The embryo-
containing dish was then placed in a humid box and covered for 5 minutes. Following 
incubation, 1.6 ml of CF-RPMI was added to the dish and placed in a 37ºC (5% CO2) incubator 
for 48 hours. 
 
Analysis of Transfected Embryos 
Secreted luciferase assay 
 Following the 48-hour incubation, 50µL of BioLux GLuc substrate was mixed with 5ml 
of BioLux GLuc Assay buffer in a glass culture tube. One blank was run to assess background 
along with 20µL of each sample mixed with 50µL of the GLuc assay solution. The luciferase 
activity was measured using an FB12 Tube Luminometer (Berthold). The activity is measured in 
relative light units (RLU). 
 
Fluorescence microscopy assay 
 Following incubation, 20µL of embryos in CF-RPMI were pipetted onto a microscope 
slide and fixed with coverslip. Various slides were observed under varying emission wavelengths 
using an automated fluorescence microscope (Zeiss).			 	
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Chapter Three: Results 
 The site-specific mutagenesis, with the goal of generating a 2-bp mutation to create a 
BclI site was confirmed by sequencing (Fig. 5). This BclI site allowed for the insertion of a 
multiple cloning site, which in turn enabled fluorescent proteins to be cloned in with the 
BmRPS12 promoter and its 3’ UTR to drive the expression. The plasmid with only the MCS was 
named pBACII-BmGluc (Fig. 6); this plasmid was transfected via biolistics and analyzed via 
luciferase assay (Fig. 12). 
 
Figure 5. Sequencing result of mutagenesis. 
Highlighted region is BclI site. 
 
 
Figure 6. Sequencing result of MCS ligation. 
Highlighted region are BclI sites flanking the MCS. 
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Prior to being cloned into the MCS, all individual inserts were cloned into the Strata 
vector as described in the methods section and confirmed by sequencing  
The first insert to be ligated into the MCS was the RPS12 3’UTR. This insert was 
amplified from the genomic DNA of B. malayi. A directional PCR screen was run on 38 
colonies, with two positive clones detected; both of these were confirmed by sequencing. 
 
Figure 7. PCR screen for RPS12 3’ UTR ligation 
 
Next, the RPS12 promoter was ligated into the MCS. Only one colony grew from the 
ligation reaction, and it was confirmed by PCR screen to have the insert in the correct orientation 
(Fig. 8). The plasmid containing the RPS12 promoter and its 3’UTR was named pBACII-
BmGluc-RPS12 and stored at -80ºC; this plasmid was used as a control for a fluorescence 
microscopy assay and a luciferase assay (Fig. 13) 
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Figure 8. PCR screen for RPS12 promoter ligation 
From left to right: Directional PCR screen, insert-specific screen, flanking screen 
 
 All of the fluorescent protein inserts were individually ligated into the MluI site, flanked 
by the RPS12 promoter and its 3’ UTR. A directional PCR screen was run for all the individual 
ligations with varying levels of success: the YFP ligation had 12 positive hits out 18 (Fig. 9); the 
GFP ligation had 6 out of 16 (Fig. 10); and the cherryRed had 1 out of 13 (Fig. 11). Only the 
construct containing YFP was transfected via biolistics into B. malayi embryos and analyzed by 
luciferase assay (Fig. 13) and fluorescence microscopy assay. 
The pBACII-BmGluc-YFP construct was analyzed by fluorescence micropsy using the 
pBACII-BmGluc-RPS12 as a control; both of these constructs were identical with the exception 
of the YFP gene. Autofluorescence was observed equally in both samples, with no significantly 
greater fluorescence in the YFP channel. 
 
 
21	
 
Figure 9. Direction PCR screen for YFP ligation 
Expected size: 1919 bp 
 
 
Figure 10. Directional PCR screen for GFP ligation 
Expected size: 2128 bp 
 
 
 
Figure 11. Directional PCR screen for CherryRed ligation 
Expected size: 1910 bp 
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Figure 12.  pBACII-BmGluc Luciferase assay. 
The two samples of embryos were transfected via biolistics with pBACII-BmGluc 
 
 
	
Figure 13.  pBACII-BmGluc-YFP Luciferase assay. 
pBACII-BmGluc-RPS12 served as a control. Both samples transfected via biolistics 	
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Chapter Four: Discussion 
 
 The luciferase assays for the three different constructs demonstrate that they were all 
successfully transfected into the embryos. The inconclusive results from the fluorescent 
microscopy assay could be due to a number of reasons. One reason may be that the RPS12 
promoter and its 3’UTR did not successfully drive the expression of the YFP. Expression of the 
YFP might have also been at a very low level, rendering it difficult to discern between 
autofluorescence and YFP-derived fluorescence. No autofluorescence was detected in 
undisturbed microfilariae and L3s. It is possible that the stress induced to prepare the embryos 
for transfection resulted in high levels of autofluorescence. Studies in the lab are currently 
ongoing to test a modified version of the in vitro transfection described in Xu et al. (2011) that 
uses a lipofection instead of a calcium phosphate precipitate-mediated transfection. This 
transfection, conducted on the more robust L3s, does not require much stress to be induced and 
could provide a method to detect fluorescence without the impeding autofluorescence. If no 
significant fluorescence is detected, a different promoter could be used or introns specific for 
BmRPS12 could be cloned in to increase the efficiency of expression. 
 These constructs could be used for spatial and temporal analysis of gene expression, 
which could elucidate gene function. In an organism with a complex life cycle like B. malayi, 
different genes will be expressed at various times throughout the life cycle. Fluorescent protein 
reporters allow researchers to monitor the gene expression in a specific cell or tissue and at 
certain times in a life cycle. Hunt-Newbury et al. (2007) used a GFP construct to generate spatial 
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and temporal tissue expression profiles for 10% of all genes in C. elegans, analyzing each stage 
of development.  
 MicroRNAs (miRNAs) play an important role in regulating posttranscriptional gene 
expression. These small RNA molecules generally form a protein complex that binds to 
sequences in the 3’UTR of mRNAs, and could be targeted for the development of novel 
treatments (Poole et al., 2014). Different miRNAs are restricted to different life cycle stages in 
nematodes, suggesting a potential role in their development. 
 miRNA activity has been analyzed using GLuc as a reporter, demonstrating that miR-71 
decreased reporter activity when inserted into the 3’UTR (Liu et al., 2015). Using GLuc as a 
reporter, however, does not all for monitoring miRNA according to different tissue types. Using 
a GFP as a reporter, Brown et al. (2006) were able to demonstrate that miR-142 was suppressed 
only in hematopoietic lineages. This result showed that GFP was an effective reporter to analyze 
how miRNAs could efficiently differentiate gene expression among different tissue types. 
 Kato et al. (2009) developed a vector system encoding two different fluorescent proteins 
(GFP & RFP). The GFP was connected to a specific miRNA (miR-133), while the RFP was not. 
The researchers demonstrated in real-time the reduction of the GFP with no effect on RFP. This 
study demonstrates how different fluorescent protein constructs could be utilized in tandem to 
more efficiently study gene regulation in varying tissue and cell types. 
 Future tools for genetic studies of Brugia malayi could be adapted from studies of other 
nematodes, especially C. elegans. CRISPR/Cas9 has been used to effectively modify the genome 
of various species to inactivate genes or knock-in desired sequences (Wei et al., 2013). Lo et al. 
(2013) demonstrated that CRISPR/Cas9 was highly effective at inducing precise indels or 
mutations that are heritable in a diverse number of nematodes, including Pristionchus pacificus 
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and C. elegans which are diverged 300 million years ago. This system also requires exogenous 
plasmids to be introduced into an organism without harm to the host. If a stable system is 
developed to introduce plasmids designed for piggyBac transfection into B. malayi, it could be 
adapted for targeted genome engineering with CRISPR/Cas9. 
 These studies could be applied to research into various drug targets. As previously 
mentioned, the current drugs mostly target the larval stages or the Wolbachia and do not have 
much of an effect on the adult stages. Several targets have been proposed, such as the nematode 
molting pathways and the nervous system (Scott & Ghedin, 2009). Filarial parasite biology is 
also of interest to human transplant research, due to the adult’s ability modulate the host immune 
reaction and persist in individuals for years without being detected by any immune reaction 
(Maizels & Yazdanbakhsh, 2003). 
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